Another novel ADC, termed Sigvotatug Vedotin, which targets Integrin beta 6 (ITGB6), was administered in a basket trial in 56 pre-treated R/M HNSCC patients. This evidence concerns the gene ITGB6 and head and neck squamous cell carcinoma.